A case report of the Modified Malmö Protocol: an alternative therapeutic approach to refractory chronic idiopathic thrombocytopenic purpura.
Therapy in refractory chronic idiopathic thrombocytopenic purpura is usually a difficult and expensive procedure, with little benefit to the patient, and the results are typically only short-term improvements. In this case report, we study a patient with refractory chronic idiopathic thrombocytopenic purpura who was initially treated with a first line therapy with only partial and temporary benefit, and in whom none of the experimental therapies tried later on resulted in any long lasting effect. In the case study conducted, among all the second-line experimental treatment modalities, only the proposed new protocol (the Modified Malmö Protocol) resulted in a major response. Our results suggest that, the Modified Malmö Protocol may be a promising second-line treatment option for severely refractory idiopathic thrombocytopenic purpura cases.
Yazman
Dilek
D
Hematology Department, Dr Burhan Nalbantoglu State Hospital, Lefkosa, Turkey. drdilekyaz@hotmail.com
Konuk
Nahide
N
Ozcan
Muhit
M
Arat
Mutlu
M
Soydan
Ender
E
Arslan
Onder
O
Ilhan
Osman
O
D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004338:Drug Combinations; D005164:Factor IX / Q000008:administration & dosage*; D005167:Factor VII / Q000008:administration & dosage*; D005169:Factor VIII / Q000008:administration & dosage*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*
D004338:Drug Combinations; D007074:Immunoglobulin G; D003520:Cyclophosphamide; D005167:Factor VII; D005169:Factor VIII; D005164:Factor IX